Stockscreener 앱 받기
10.33
4.44%
-0.48
시장 영업 전:
10.40
0.07
+0.68%
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix Inc. stock trend outlook and recovery pathShort Squeeze Opportunities with Indicators - Newser
Is CorMedix Inc. part of any ETFShort-Term Gainers List - thegnnews.com
CorMedix Inc. stock trend forecastFree Real-Time Analysis With Entry Targets - Newser
Strategic Value and Growth Potential of CorMedix Post-Melinta Acquisition - AInvest
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - Stocktwits
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
Cormedix Inc Reports Q2 2025 Earnings: $39.7M in Revenue, $0.29 EPS, and Acquisition of Melinta Therapeutics - AInvest
Applying big data sentiment scoring on CorMedix Inc.Free Consistent Income Focused Trade List - Newser
HC Wainwright Maintains Buy Rating on Cormedix, Adjusts Price Target to $17.00 - AInvest
Unraveling the Drop in CorMedix (CRMD.O): A Technical and Market Flow Deep Dive - AInvest
Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ... By GuruFocus - Investing.com Canada
CorMedix signs agreement to acquire Melinta for $300m - Yahoo Finance
CorMedix Inc. Reports Strong Q2 2025 Results - TipRanks
Transcript : CorMedix Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
CorMedix: Q2 Earnings Snapshot - Stamford Advocate
Cormedix’s Strategic Growth Potential Boosted by Melinta Therapeutics Acquisition - TipRanks
CorMedix (CRMD.O) Suffers Sharp Intraday Drop: What’s the Story Behind? - AInvest
CRMD Faces Major Legal Battle - StocksToTrade
CorMedix Surpasses Expectations with Q2 Earnings Surge - AInvest
CorMedix Forecasts FY25 Pro Forma Revenue of $305M-$335M - AInvest
M&A News: CorMedix Stock (CRMD) Plunges 11% Despite $300M Melinta Deal - TipRanks
CorMedix buys Melinta Therapeutics for $300M - ROI-NJ
Cormedix Inc. shares fall 11.38% intraday after announcing $260M acquisition of Melinta Therapeutics, raising dilution and financing concerns. - AInvest
CorMedix To Acquire Melinta Therapeutics In $300 Mln Deal To Expand Infectious Disease Portfolio - Nasdaq
CorMedix to Buy Melinta Therapeutics for $300 Million - The Wall Street Journal
CorMedix to acquire Melinta Therapeutics for $300M - TipRanks
CorMedix Inc. SEC 10-Q Report - TradingView
CorMedix Announces Merger Agreement with Melinta Therapeutics - TipRanks
CorMedix To Acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence In Acute Care Settings - TradingView
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
CorMedix reports Q2 EPS 28c, consensus 19c - TipRanks
CorMedix earnings beat by $0.12, revenue topped estimates - Investing.com Canada
CorMedix to acquire Melinta Therapeutics in $300 million deal - Investing.com
CorMedix Acquires Seven Drug Products, Expands Revenue to $305-335mln by 2025. - AInvest
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings - The Manila Times
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Press Release: Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
$300M CorMedix-Melinta Deal Creates Powerhouse with $335M Revenue Potential, 7 Acute Care Products - Stock Titan
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - The Globe and Mail
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release - Yahoo Finance
iShares Morningstar Small-Cap ETF Holdings Could Mean 18% Gain Potential - AInvest
What makes CorMedix Inc. stock price move sharplyConsistent double returns - Jammu Links News
What drives CorMedix Inc. stock priceMarket-leading capital gains - Jammu Links News
What catalysts could drive CorMedix Inc. stock higher in 2025Track high-yield stocks before they peak - Jammu Links News
When is CorMedix Inc. stock expected to show significant growthExtraordinary market timing - Jammu Links News
Should I hold or sell CorMedix Inc. stock in 2025Unlock steady growth with low-risk stocks - Jammu Links News
How does CorMedix Inc. generate profit in a changing economyExceptional return forecasts - Jammu Links News
How many analysts rate CorMedix Inc. as a “Buy”Achieve consistent double-digit growth - Jammu Links News
Is CorMedix Inc. stock overvalued or undervaluedExplosive capital gains - Jammu Links News
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect? - Yahoo Finance
CorMedix Inc. (CRMD) Stock Analysis: Exploring a 64% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - The Globe and Mail
What are the technical indicators suggesting about CorMedix Inc.Best Dividend Report With High Returns - Jammu Links News
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - The Globe and Mail
Is CorMedix Inc. Forming a Bottom PatternProfit Focused Stock Screener Results Released - metal.it
CorMedix Inc. recovery potential after sell offBuy Alerts With Low Risk Confirmation Noted - metal.it
Published on: 2025-07-29 17:35:04 - metal.it
Live Scanner Shows Breakout on CorMedix Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Are Bears Losing Grip on CorMedix Inc.Real Time Stock Movement Analysis Indicates Breakout - beatles.ru
0.24%
3.39%
자본화:
|
볼륨(24시간):